Inherited and acquired defects in homologous recombination, a phenotype termed 'BRCAness', may lend to therapeutic exploitation in breast cancer. To this end, development and clinical evaluation of platforms to identify signatures of BRCAness are of immense interest. In this issue of Breast Cancer Research, Vollebergh and colleagues report that a BRCA-like array comparative genomic hybridization (aCGH) genomic instability signature is associated with benefit from high-dose cyclophosphamide-thiotepa-carboplatin chemotherapy. We discuss the strengths and weaknesses of this study and consider the clinical significance and applicability of this aCGH BRCAness signature in the context of other existing homologous recombination deficiency detection platforms.
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In this issue of Breast Cancer Research, Vollebergh and colleagues [1] report on the predictive capacity of an array comparative genomic hybridization (aCGH) signature resembling BRCA1-and BRCA2-mutant breast cancers. The BRCA1 and BRCA2 genes are required for DNA double-strand break (DSB) and interstrand crosslink repair by homologous recombination (HR) [2, 3] . Pre-clinical and clinical data suggest that cancers arising in BRCA1 and BRCA2 mutation carriers are particularly responsive to agents that lead to DSBs (for example, platinum salts and poly(ADP-ribose) polymerase (PARP) inhibitors) [4] [5] [6] . Although inherited mutations in BRCA1 and BRCA2 account for only 5 % to 10 % of all breast cancers, these and other genes which operate in the HR pathway may be altered by mutation, Vollebergh and colleagues retrospectively assessed a subset of HER-2-negative tumor specimens from a randomized clinical trial that compared five cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FE 90 C) with four cycles of FE 90 C followed by high-dose cyclophosphamide-thiotepa-carboplatin (HD-CTC) with autologous stem cell support in patients with at least four positive axillary lymph nodes. The BRCA1-and BRCA2-like aCGH profiles were based on previous work by this group and were generated on 249 HER-2-negative formalin-fixed paraffin-embedded (FFPE) tumor samples [10] . Overall, the BRCA-like cgh profile was detected in 32 % (12 % BRCA1-like, 15 % BRCA2-like, and 5 % both BRCA1-and BRCA2-like) of the study cohort and predicted benefit from HD-CTC in both TNBC and hormone receptor-positive breast cancer. HD-CTC was associated with improved overall survival compared with FE 90 C in patients with BRCA-like cgh tumors but not in patients with non-BRCA-like cgh tumors. As expected, a significant proportion (76 %) of TNBCs harbored the BRCA-like cgh profile. Interestingly, 28 % of hormone receptor-positive tumors also demonstrated the BRCAlike cgh profile. This aCGH platform is attractive as it allows detection of genomic instability resulting from HR deficiency without requiring identification of the precise molecular etiology. If validated in other cohorts, this assay could potentially identify patients destined to benefit from intensified DNA-damaging therapy.
Despite the future potential of this aCGH platform as a predictive marker, the present study has important limitations. First, the HD-CTC regimen included both carboplatin and intensified alkylating chemotherapy (cyclophosphamide and thiotepa) and therefore it remains unclear whether the benefit observed in the BRCA-like cgh patients within the experimental cohort was due to the platinum or the intensified alkylating agents or both. This is a significant confounder and complicates interpretation of these data. Additionally, although this study included a high-risk population (at least four positive nodes), neither the experimental (HD-CTC) nor the control (taxane-devoid chemotherapy) regimens are considered standard for node-positive breast cancer in this era. Evaluation of this assay in cohorts treated with contemporary neoadjuvant chemotherapy regimens is encouraged.
Currently, a standard platform for detecting BRCAness has not reached routine clinical application, but several functional assays besides the aCGH platform described by Vollebergh and colleagues have emerged. The homologous recombination deficiency (HRD) assay developed by Myriad Genetics, Inc. (Salt Lake City, UT, USA) evaluates tumor genome loss of heterozygosity, telomeric allelic imbalance (TAI), and large-scale state transitions, which are all indirect measures of tumor genomic instability. High HRD scores are highly correlated with defects in BRCA1/2 and are associated with sensitivity to neoadjuvant platinum-based chemotherapy in TNBC [9, 11] . Another study examining TAI in sporadic TNBC has shown that tumors with high levels of TAI respond better to neoadjuvant platinum chemotherapy [7] . In addition to exhibiting genomic instability, tumors with BRCAness may exhibit characteristic gene expression patterns. Mulligan and colleagues [8] recently reported on a 44-gene DNA damage response deficiency signature (DDRDS) which was developed in cohorts enriched for germline BRCA1/2 and Fanconi anemia mutations. The DDRDS is enriched for immune responserelated genes and predicted favorable response to FE 90 C chemotherapy in both TNBC and hormone receptorpositive breast cancer. The aCGH, HRD, TAI, and DDRDS platforms are all compatible with FFPE tissues, making them suitable for prospective studies. Furthermore, all of these HR deficiency platforms suggest that the BRCAness phenotype exists in at least half of patients with TNBC and one quarter of patients with hormone receptorpositive breast cancer, implying future predictive applicability to a large fraction of patients with breast cancer.
There is now renewed interest in the efficacy of platinum agents for the treatment of TNBC as recent randomized trials have demonstrated improvement in pathological complete response rates with the addition of neoadjuvant carboplatin to anthracycline/taxanebased chemotherapy [12] [13] [14] . HR deficiency assay assessments on the completed randomized neoadjuvant platinum trials are eagerly awaited and will help identify patients most likely to benefit from such an approach. Whether HR deficiency assays will predict benefit from PARP inhibitors in addition to DNA-damaging chemotherapy also remains to be seen.
Employing functional measures of HR pathway deficiency rather than relying on documented changes in specific genes should capture more patients who might benefit from DNA-damaging therapies, and Vollebergh and colleagues should be congratulated on developing one such assay. However, before HR deficiency assays can be used for medical utility, the recognized steps for incorporation of predictive biomarkers into clinical care (that is, additional validation studies and assessment within prospective randomized trials) have to be fulfilled [15] . If appropriately validated, HR deficiency assays could have tremendous impact on patient care by identifying patients most likely to benefit from DNA-damaging agents like platinum salts or PARP inhibitors or both.
In conclusion, considerable strides have been made in analytical development and early clinical validation of functional HR deficiency assays and these efforts bring us one step closer to the eventual utilization of BRCAness as a guide to personalize treatment with DNAdamaging agents in patients with breast cancer. Competing interests PS receives research funding from GlaxoSmithKline (Uxbridge, UK), Myriad Genetics, Inc., Novartis (Basel, Switzerland), and Roche (Basel, Switzerland). SRS declares that he has no competing interests. 
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